API Fevipiprant NVP - QAW039 Anti Estrogen Steroids CAS 872365-14-5
Place of Origin | China |
---|---|
Brand Name | XRD |
Certification | GMP |
Model Number | 872365-14-5 |
Minimum Order Quantity | negotiable |
Price | Inquiry for Negotiable |
Packaging Details | 1-2 kg / aluminum foil bag, 25kg/ drum, as required |
Delivery Time | 1-2days after payment received |
Payment Terms | T/T bank, Western Union, Bitcoin, Etc |
Supply Ability | 100KG/ Month |

Contact me for free samples and coupons.
Whatsapp:0086 18588475571
Wechat: 0086 18588475571
Skype: sales10@aixton.com
If you have any concern, we provide 24-hour online help.
xCAS | 872365-14-5 | Product Name | Fevipiprant |
---|---|---|---|
Type | Anti-hair Loss Powder | Appearance | White Powder |
Usage | Anti-hair Loss Powder | Alias | Fevipiprant |
Assay | 99% | Key Words | Fevipiprant |
High Light | anti estrogen steroids,hair growing powder |
Anti-hair Loss Powder API Fevipiprant(NVP-QAW039) Fevipiprant CAS 872365-14-5
Quick Details
Name | Formestane |
CAS No. | 566-48-3 |
EINECS | N/A |
MF | C19H26O3 |
MW | 302.41 |
MP | 199-202°C |
Storage temp. | 2-8°C |
Purity | 99% min |
Usage | An antitumor drug. An aromatase inhibitor |
Appearance | Needles |
Formestane also is known as lentaron,is an anti-cancer drug, it is primarily used for the treatment of postmenopausal women with advanced breast cancer, it is also effective in prostate cancer
Introduction:
1) Product Name:Supply Anti-hair Fevipiprant powder CAS 872365-14-5
2) Purity: ≥99%
3) Appearance: White fine powder
4) Introduction:
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[1][2][3
As of 2016, it is in Phase III[4] clinical trials for the treatment of asthma.[5]
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2).[1] It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3] it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Anti-hair Loss Powder API Fevipiprant(NVP-QAW039) Fevipiprant CAS 872365-14-5